journal article·2020-05

Prodrug‐Based Versatile Nanomedicine for Enhancing Cancer Immunotherapy by Increasing Immunogenic Cell Death

Shuang Bai, Lei‐Lei Yang, Yajun Wang, Tian Zhang, Lvqin Fu, Shaochen Yang, Shucheng Wan, Shuo Wang, Die Jia, Baosheng Li, Peng Xue, Yuejun Kang, Zhi‐Jun Sun, Zhigang Xu

Small· Volume 16· Issue 19
Publisher page

Abstract

Abstract Nanoparticle‐based tumor immunotherapy has emerged to show great potential for simultaneously regulating the immunosuppressive tumor microenvironment, reducing the unpleasant side effects, and activating tumor immunity. Herein, an excipient‐free glutathione/pH dual‐responsive prodrug nanoplatform is reported for immunotherapy, simply by sequentially liberating 5‐aminolevulinic acid and immunogenically inducing doxorubicin drug molecules, which can leverage the acidity and reverse tumor microenvironment. The obtained nanoplatform effectively boosts the immune system by promoting dendritic cell maturation and reducing the number of immune suppressive immune cells, which shows the enhanced adjunctive effect of anti‐programmed cell death protein 1 therapy. Overall, the prodrug‐based immunotherapy nanoplatform may offer a reliable strategy for improving synergistic antitumor efficacy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer Immunotherapy and Biomarkers · Phagocytosis and Immune Regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Materials and Energy and Chongqing Engineering Research Center for Micro–Nano Biomedical Materials and Devices Southwest University Chongqing 400715 P. R. China

The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei‐MOST) and Key Laboratory of Oral Biomedicine Ministry of Education School and Hospital of Stomatology Wuhan University Wuhan 430079 P. R. China

School of Chemistry and Chemical Engineering Chongqing University Chongqing 400044 P. R. China

Funding

National Natural Science Foundation of China · National Basic Research Program of China · Chongqing Basic and Frontier Research Project

References (54)

Show source-provided references
1. 10.1126/science.aar406010.1126/science.aar4060 ↗
2. 10.1038/nature1067310.1038/nature10673 ↗
3. 10.1016/j.cell.2018.09.03510.1016/j.cell.2018.09.035 ↗
4. 10.1056/NEJMoa150182410.1056/NEJMoa1501824 ↗
5. 10.1056/NEJMoa141108710.1056/NEJMoa1411087 ↗
6. 10.1200/JCO.2014.56.273610.1200/JCO.2014.56.2736 ↗
7. 10.1016/j.ejca.2015.08.01210.1016/j.ejca.2015.08.012 ↗
8. 10.1016/j.cell.2017.01.01710.1016/j.cell.2017.01.017 ↗
9. 10.1038/s41571-018-0142-810.1038/s41571-018-0142-8 ↗
10. 10.1158/0008-5472.CAN-16-237910.1158/0008-5472.CAN-16-2379 ↗
11. 10.1002/adfm.20180468810.1002/adfm.201804688 ↗
12. 10.1002/adma.20190253010.1002/adma.201902530 ↗
13. 10.1002/adfm.20190660510.1002/adfm.201906605 ↗
14. 10.1021/acs.nanolett.9b0058410.1021/acs.nanolett.9b00584 ↗
15. 10.1038/nrc338010.1038/nrc3380 ↗
16. 10.1038/nri.2016.10710.1038/nri.2016.107 ↗
17. 10.1002/adma.20190433710.1002/adma.201904337 ↗
18. 10.1021/acsnano.9b0604010.1021/acsnano.9b06040 ↗
19. 10.1002/adfm.20180608710.1002/adfm.201806087 ↗
20. 10.1002/smll.20190026210.1002/smll.201900262 ↗
21. 10.1002/smll.20180067810.1002/smll.201800678 ↗
22. 10.1002/adma.20190427810.1002/adma.201904278 ↗
23. 10.1016/j.bbcan.2018.11.00410.1016/j.bbcan.2018.11.004 ↗
24. 10.1002/advs.20190032710.1002/advs.201900327 ↗
25. 10.1016/j.biomaterials.2019.11942210.1016/j.biomaterials.2019.119422 ↗
26. 10.1002/smll.20180413110.1002/smll.201804131 ↗
27. 10.1002/anie.20190396810.1002/anie.201903968 ↗
28. 10.1021/acs.accounts.9b0012610.1021/acs.accounts.9b00126 ↗
29. 10.1002/smll.20190683210.1002/smll.201906832 ↗
30. 10.1016/j.jconrel.2016.06.01710.1016/j.jconrel.2016.06.017 ↗
31. 10.1038/nrc.2016.10810.1038/nrc.2016.108 ↗
32. 10.1021/cr500463410.1021/cr5004634 ↗
33. 10.1016/j.ejmech.2019.11158210.1016/j.ejmech.2019.111582 ↗
34. 10.1016/j.biomaterials.2019.01.04410.1016/j.biomaterials.2019.01.044 ↗
35. 10.1038/nrc325810.1038/nrc3258 ↗
36. 10.1007/s00262-011-1184-210.1007/s00262-011-1184-2 ↗
37. 10.1084/jem.2005091510.1084/jem.20050915 ↗
38. 10.1016/j.cytogfr.2013.01.00510.1016/j.cytogfr.2013.01.005 ↗
39. 10.1146/annurev-immunol-032712-10000810.1146/annurev-immunol-032712-100008 ↗
40. 10.1016/j.cell.2005.08.03210.1016/j.cell.2005.08.032 ↗
41. 10.1038/nm152310.1038/nm1523 ↗
42. 10.1038/nm162210.1038/nm1622 ↗
43. 10.1084/jem.192.4.56510.1084/jem.192.4.565 ↗
44. 10.1182/blood-2004-10-390610.1182/blood-2004-10-3906 ↗
45. 10.1038/nature0829610.1038/nature08296 ↗
46. 10.1038/nm.202810.1038/nm.2028 ↗
47. 10.1016/j.ccell.2015.10.01210.1016/j.ccell.2015.10.012 ↗
48. 10.1158/0008-5472.CAN-13-154510.1158/0008-5472.CAN-13-1545 ↗
49. 10.1016/S0092-8674(00)81683-910.1016/S0092-8674(00)81683-9 ↗
50. 10.1146/annurev-immunol-041015-05531810.1146/annurev-immunol-041015-055318 ↗
51. 10.1002/adfm.20190244010.1002/adfm.201902440 ↗
52. 10.1002/adma.20180500710.1002/adma.201805007 ↗
53. 10.1172/JCI9797310.1172/JCI97973 ↗
54. 10.1146/annurev.immunol.21.120601.14112210.1146/annurev.immunol.21.120601.141122 ↗